One BCMA-targeted and four CD19-targeted CAR-T products have been approved for marketing by the American Food and Drug Administration (FDA): tisagenlecleucel and axicabtagene ciloleucel for the treatment of relapsed/refractory (R/R) large B-cell lymphoma and pediatric B-cell acute lymphocytic leukemia, brexucabtagene autoleucel for R/R mantle cell lymphoma, lisocabtagene maraleucel for R/R large B-cell lymphoma, and idecabtagene vicleucel for R/R multiple myeloma [1–5]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.